Express Pharma

AUGUST 13, 2024

per cent between 2020 and 2030. Many of these therapies are used off label. Filippos Maniatis, Healthcare Analyst at GlobalData, states, “It is an exciting time for the treatment landscape of AD as multiple therapies are coming closer to approval. Vtama and Zoryve possess interesting mechanisms of action (MoAs).

Labelling 97

Labelling 97

European Pharmaceutical Review

FEBRUARY 8, 2023

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7

Labelling 98

Labelling Compounding 98

Express Pharma

JANUARY 4, 2024

The Indian pharma industry is on a solid growth trajectory, surging from $40 billion in 2021 to an estimated $130 billion in 2030, with a steady double-digit CAGR for the next 10 years. In addition to meeting strong domestic demand, the Indian pharmaceutical industry is well poised as a robust contributor to the growing global market.

Packaging 108

Packaging Labelling Vaccines 108

Pharmaceutical Business Review

JUNE 2, 2023

We look forward to pivotal studies that will enable VOLT01 to have a label for pain relief of osteoarthritis in all joints along with disease modification after a single yearly infusion.” “More importantly, VOLT01 showed disease modifying activity as measured by MRI with pain relief correlating with disease modification. “We

Labelling 52

Labelling 52

Express Pharma

JULY 28, 2024

Several US KOLs have acknowledged that they utilise Nuzyra off-label for the treatment of NTM-PD caused by the species Mycobacterium abscessus and M. According to GlobalData estimates, Nuzyra for the treatment of NTM-PD is expected to launch in the US in 2029 and in the EU in 2030. avium complex (MAC).

Labelling 78

Labelling 78

Pharma Leaders

JUNE 2, 2023

We look forward to pivotal studies that will enable VOLT01 to have a label for pain relief of osteoarthritis in all joints along with disease modification after a single yearly infusion.” “More importantly, VOLT01 showed disease modifying activity as measured by MRI with pain relief correlating with disease modification. “We

Labelling 52

Labelling 52

Express Pharma

MAY 13, 2024

billion by 2030, subject to approval, and the competition in the bronchiectasis treatment landscape is expected to increase over the next few years. According to GlobalData’s Sales and Forecast database, brensocatib’s sales are anticipated to reach $1.2

Pharmaceutical Companies 96

Pharmaceutical Companies Pharmaceutical Companies Labelling 96

Quality Matters

SEPTEMBER 9, 2024

billion in 2024 to over 32 billion in 2030. By engaging in roundtable discussions, drafting stimuli articles, and developing work plans with HQS Expert Committees, USP is setting high-quality standards, covering aspects such as labeling, version control, classification, health equity, and accessibility.

Labelling 52

Labelling Diabetes 52

Pharmaceutical Technology

JUNE 7, 2023

In addition, Mounjaro is estimated to gain sales of around $20bn by 2030 and become the leading GLP-1 in the obesity market, as well as in T2D. Mounjaro’s approval in 2022 for T2D has already led to many prescribers providing the therapy off-label to their patients to help them lose weight.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Labelling Diabetes 98

pharmaphorum

NOVEMBER 6, 2022

The antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies and those with a range of health conditions that could make the vulnerable to RSV, said the two pharma groups in a statement. It is the first approval for Beyfortus (nirsevimab) by any regulatory authority.

Vaccines 64

Vaccines Labelling 64

pharmaphorum

JANUARY 19, 2023

.” A recent report from Clarivate highlighted ritlecitinib as one of 14 potential blockbusters to watch this year, pointing to its rapid onset of action and expected label for both adults and adolescents – Olumiant is so far only approved for use in adults. The report predicts that the alopecia areata market will grow to as much as $2.5

Labelling 94

Labelling Immunity Immunization 94

pharmaphorum

FEBRUARY 22, 2022

The FDA has approved expanded labelling for Abbott’s CardioMEMS HF System, an implantable sensor that provides an early warning of worsening heart failure, that could make it an option for more than a million more patients. More than 6.2

Labelling 64

Labelling 64

Quality Matters

MARCH 1, 2024

market by 2030, and this growth is not limited to the U.S., In the meantime, USP encourages interested parties to reach out for more information as USP approaches its new 2025-2030 cycle. The DTx landscape is evolving rapidly, with more than 40 prescription digital therapeutics already available in the U.S. in the U.S.

Labelling 52

Labelling Compounding 52

pharmaphorum

MARCH 8, 2022

He is giving Trodelvy a 40% chance of approval and launch with a third-line label in HR+/HER2- breast cancer in 2024, with $900 million in potential sales from the indication, if TROPiCS-02 is positive at the final readout. The company said it “remains confident in that goal.” appeared first on.

Chemotherapy 52

Chemotherapy Documentation Labelling 52

Pharma Marketing Network

MARCH 25, 2022

By 2030, it is estimated there will be only 4 potential family caregivers per older adult and some are also caring for children of their own. Pharma can help with caregiver-relevant labeling, training to perform nursing duties, and a multitude of other support services.

Labelling 98

Labelling Drug Development 98

Fuld & Company Blog

FEBRUARY 6, 2023

It is estimated that the global people analytics market is set grow five-fold to over US$10 billion by 2030, driven by its increasing adoption, While there are several implementation success stories, many organizations still struggle to derive optimum value. These biases can creep into AI models and their recommendations.

Communication 52

Communication Labelling 52

Express Pharma

MAY 22, 2023

This, in turn, has opened a huge opportunity for the nutraceuticals industry globally and India is uniquely positioned to become one of the most formidable players in this segment, with a projected $100 billion valued market by 2030. Read: [link] www.expresspharma.in/six-reasons-why-india-is-poised-to-be-aglobal-leader-in-nutraceuticals/

Dosage 101

Dosage Method Validation Labelling Immunity 101

Pharmacy Friday Pearls

MARCH 9, 2022

2001;161(16):2030-6. vs 10.3% • p < 0.05, NNT = 5 Gerardo CJ, 2017 RCT in 18 ED in the US (n = 74) Crofab ® versus placebo to measure limb function 14 days after envenomation using Patient-Specific Functional Scale Crofab reduced limb disability measured by the Patient-Specific Functional Scale 14 days after copperhead envenomation. •

Immunity 40

Immunity Immunization Packaging Labelling 40

pharmaphorum

NOVEMBER 10, 2022

With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity. Everyone has a mobile: now is the age of electronic patient information; now is the time for electronic labelling. Nonetheless, with regards to research, we are living in a renaissance age, she argued, in terms of prevention, as much as treatment.

Vaccines 92

Vaccines Biosimilars Labelling Pharmaceutical Companies 92

PharmaShots

APRIL 3, 2023

of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. 4 approved medicines across solid tumors & hematologic malignancies, incl. 3 ADCs: Adcetris, Padcev & Tivdak.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

European Pharmaceutical Review

DECEMBER 1, 2022

Between 2016 and 2019, DNDi and its partners led an open-label, Phase II/III study to assess the safety and efficacy of acoziborole in patients with early- and late-stage g-HAT. In alignment with the World Health Organization (WHO) Neglected Tropical Diseases Roadmap strategy, which aims to eliminate sleeping sickness by 2030.

Labelling 98

Labelling Hospitals 98

Pharmaceutical Technology

DECEMBER 22, 2022

By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA. However, he did point out that the joint assessment could be a useful way of narrowing down typically broad EMA label content to specific patient populations. As part of the decision-making process, they may request further evidence.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Communication 52